Your browser doesn't support javascript.
Demographics, Outcomes, and Risk Factors for Patients with Sarcoma and COVID-19: A CCC19-Registry Based Retrospective Cohort Study.
Wagner, Michael J; Hennessy, Cassandra; Beeghly, Alicia; French, Benjamin; Shah, Dimpy P; Croessmann, Sarah; Vilar-Compte, Diana; Ruiz-Garcia, Erika; Ingham, Matthew; Schwartz, Gary K; Painter, Corrie A; Chugh, Rashmi; Fecher, Leslie; Park, Cathleen; Zamulko, Olga; Trent, Jonathan C; Subbiah, Vivek; Khaki, Ali Raza; Tachiki, Lisa; Nakasone, Elizabeth S; Loggers, Elizabeth T; Labaki, Chris; Saliby, Renee Maria; McKay, Rana R; Ajmera, Archana; Griffiths, Elizabeth A; Puzanov, Igor; Tap, William D; Hwang, Clara; Tejwani, Sheela; Jhawar, Sachin R; Hayes-Lattin, Brandon; Wulff-Burchfield, Elizabeth; Kasi, Anup; Reuben, Daniel Y; Nagaraj, Gayathri; Joshi, Monika; Polimera, Hyma; Kulkarni, Amit A; Esfahani, Khashayar; Kwon, Daniel H; Paoluzzi, Luca; Bilen, Mehmet A; Durbin, Eric B; Grivas, Petros; Warner, Jeremy L; Davis, Elizabeth J.
  • Wagner MJ; Department of Medicine, University of Washington, and Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
  • Hennessy C; Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
  • Beeghly A; Department of Medicine, Division of Epidemiology, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
  • French B; Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
  • Shah DP; Department of Population Health Sciences, UT Health San Antonio, San Antonio, TX 78229, USA.
  • Croessmann S; Department of Medicine, Division of Hematology and Oncology, Vanderbilt University, Nashville, TN 37232, USA.
  • Vilar-Compte D; Department of Infectious Diseases, Instituto Nacional de Cancerología, Mexico City 14080, Mexico.
  • Ruiz-Garcia E; Department of Infectious Diseases, Instituto Nacional de Cancerología, Mexico City 14080, Mexico.
  • Ingham M; Department of Medicine, Columbia University Irving Medical Center, New York, NY 10032, USA.
  • Schwartz GK; Department of Medicine, Columbia University Irving Medical Center, New York, NY 10032, USA.
  • Painter CA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
  • Chugh R; Department of Hematology and Oncology, University of Michigan, Ann Arbor, MI 48109, USA.
  • Fecher L; Department of Hematology and Oncology, University of Michigan, Ann Arbor, MI 48109, USA.
  • Park C; University of Cincinnati Cancer Center, Cincinnati, OH 45267, USA.
  • Zamulko O; University of Cincinnati Cancer Center, Cincinnati, OH 45267, USA.
  • Trent JC; Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL 33136, USA.
  • Subbiah V; Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Khaki AR; Department of Medicine, Stanford University, Stanford, CA 94304, USA.
  • Tachiki L; Department of Medicine, University of Washington, and Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
  • Nakasone ES; Department of Medicine, University of Washington, and Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
  • Loggers ET; Department of Medicine, University of Washington, and Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
  • Labaki C; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
  • Saliby RM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
  • McKay RR; Department of Medicine, Moores Cancer Center, University of California San Diego, San Diego, CA 92037, USA.
  • Ajmera A; Department of Medicine, Moores Cancer Center, University of California San Diego, San Diego, CA 92037, USA.
  • Griffiths EA; Department of Medicine, Roswell Park Comprehensive Cancer Center, University of Buffalo, Buffalo, NY 14203, USA.
  • Puzanov I; Department of Medicine, Roswell Park Comprehensive Cancer Center, University of Buffalo, Buffalo, NY 14203, USA.
  • Tap WD; Department of Medical Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.
  • Hwang C; Henry Ford Cancer Institute, Detroit, MI 48202, USA.
  • Tejwani S; Henry Ford Cancer Institute, Detroit, MI 48202, USA.
  • Jhawar SR; Department of Radiation Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA.
  • Hayes-Lattin B; Division of Hematology and Medical Oncology, Knight Cancer Institute at Oregon Health and Science University, Portland, OR 97239, USA.
  • Wulff-Burchfield E; Department of Medicine, The University of Kansas Medical Center, Kansas City, KS 66103, USA.
  • Kasi A; Department of Medicine, The University of Kansas Medical Center, Kansas City, KS 66103, USA.
  • Reuben DY; Hollings Cancer Center, Medical University of South Carolina, Charleston, SC 29425, USA.
  • Nagaraj G; Division of Hematology and Oncology, Loma Linda University School of Medicine, California, CA 92354, USA.
  • Joshi M; Department of Medicine, Division of Hematology-Oncology, Penn State Cancer Institute, Hershey, PA 17033, USA.
  • Polimera H; Department of Medicine, Division of Hematology-Oncology, Penn State Cancer Institute, Hershey, PA 17033, USA.
  • Kulkarni AA; Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA.
  • Esfahani K; Segal Cancer Centre, Jewish General Hospital, McGill University, Montreal, QC H4A 3J1, Canada.
  • Kwon DH; UCSF Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, California, CA 94117, USA.
  • Paoluzzi L; Department of Oncology, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY 10467, USA.
  • Bilen MA; Department of Oncology, Emory University, Atlanta, GA 30322, USA.
  • Durbin EB; Division of Biomedical Informatics, College of Medicine, University of Kentucky, Lexington, KY 40536, USA.
  • Grivas P; Department of Medicine, University of Washington, and Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
  • Warner JL; Department of Medicine, Division of Hematology and Oncology, Vanderbilt University, Nashville, TN 37232, USA.
  • Davis EJ; Department of Biomedical Informatics, Vanderbilt University, Nashville, TN 37232, USA.
Cancers (Basel) ; 14(17)2022 Sep 05.
Article in English | MEDLINE | ID: covidwho-2009955
ABSTRACT

BACKGROUND:

Patients with sarcoma often require individualized treatment strategies and are likely to receive aggressive immunosuppressive therapies, which may place them at higher risk for severe COVID-19. We aimed to describe demographics, risk factors, and outcomes for patients with sarcoma and COVID-19.

METHODS:

We performed a retrospective cohort study of patients with sarcoma and COVID-19 reported to the COVID-19 and Cancer Consortium (CCC19) registry (NCT04354701) from 17 March 2020 to 30 September 2021. Demographics, sarcoma histologic type, treatments, and COVID-19 outcomes were analyzed.

RESULTS:

of 281 patients, 49% (n = 139) were hospitalized, 33% (n = 93) received supplemental oxygen, 11% (n = 31) were admitted to the ICU, and 6% (n = 16) received mechanical ventilation. A total of 23 (8%) died within 30 days of COVID-19 diagnosis and 44 (16%) died overall at the time of analysis. When evaluated by sarcoma subtype, patients with bone sarcoma and COVID-19 had a higher mortality rate than patients from a matched SEER cohort (13.5% vs 4.4%). Older age, poor performance status, recent systemic anti-cancer therapy, and lung metastases all contributed to higher COVID-19 severity.

CONCLUSIONS:

Patients with sarcoma have high rates of severe COVID-19 and those with bone sarcoma may have the greatest risk of death.
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study Language: English Year: 2022 Document Type: Article Affiliation country: Cancers14174334

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study Language: English Year: 2022 Document Type: Article Affiliation country: Cancers14174334